ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Protective potential of linalool against cyclophosphamide-induced interstitial cystitis: mechanistic insights from experimental and computational approaches.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Interstitial cystitis (IC) is an adverse event associated with the use of cyclophosphamide (CYP), an alkylating anticancer agent, caused by oxidative stress and excessive production of proinflammatory cytokines. The bladder becomes overactive. This study aims to evaluate linalool's ability to treat CYP-induced IC. To induce IC, a 150 mg/kg intraperitoneal (i.p.) dose of CYP was administered to female Sprague Dawley rats on days 1, 4, and 7. To assess the protective potential of linalool, macroscopic evaluation, nociception response, Evans blue dye test, and the role of antioxidant and inflammatory mediators were investigated. Linalool is an acyclic monoterpene tertiary alcohol. It makes up almost 70% of the terpenoids found in flower fragrances. In this study, oral linalool at doses of 25, 50, and 100 mg/kg significantly reduced inflammation (P < 0.05). Compared to the CYP-treated group, linalool markedly increased mRNA expression (P < 0.05) of superoxide dismutase (SOD), catalase (CAT), glutathione reductase (GSH), and interleukin-10 (IL-10) levels, while decreasing mRNA expression of inducible nitrous oxide synthase (iNOS), tissue growth factor-β1 (TGF-β1), and tissue necrosis factor-α (TNF-α). The anti-inflammatory and antioxidant properties of linalool were further confirmed by molecular docking with specific protein targets. Linalool reduced CYP-induced bladder overactivity by blocking muscarinic 3 (M
Indexed as
Identifiers
41746319What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.